PipelineReview.com1d
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks ...
PipelineReview.com1d
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
WALTHAM, MA, USA & MONTREAL, Canada I May 03, 2024 I Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry ...
PipelineReview.com2d
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors - ...
PipelineReview.com2d
Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma
BOSTON, MA, USA and VANCOUVER, Canada I May 2, 2024 I Alpha-9 Oncology (Alpha-9), a clinical stage company developing radiopharmaceuticals for the treatment of cancer patients worldwide, announced ...
PipelineReview.com2d
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
PHILADELPHIA, PA, USA I May 02, 2024 I Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the ...
PipelineReview.com2d
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
BASEL, Switzerland I May 2, 2024 I Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage ...
PipelineReview.com2d
Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1
GUANGZHOU, China I May 02, 2024 I Guangzhou Bio-gene Technologies, a biotechnology company engaged in the discovery, development, and delivery of novel cell therapies for the treatment of blood ...
PipelineReview.com2d
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases ...
PipelineReview.com4d
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
SOUTH SAN FRANCISCO, CA, USA I April 30, 2024 I Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart’s oral pill ...
PipelineReview.com5d
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
SAN DIEGO, CA, USA, and MUNICH, Germany I April 29, 2024 I selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T-cell ...
PipelineReview.com3d
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
BEIJING and SHANGHAI, China and BOSTON, MA, USA I April 30, 2024 I Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of ...
PipelineReview.com4d
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
NEW YORK, NY, USA I April 30, 2024 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell ...